United States
Print page content Print
Increase text size Decrease text size
Text Size
MOA Top Banner

What is the indication for Canine Atopic Dermatitis Immunotherapeutic*?

Canine Atopic Dermatitis Immunotherapeutic* aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

How does Canine Atopic Dermatitis Immunotherapeutic* work?

Canine Atopic Dermatitis Immunotherapeutic* is a ready-to-use, sterile liquid containing caninized anti-cIL-31 monoclonal antibody (mAb). This mAb specifically targets and neutralizes canine interleukin (IL)-31, which is involved in sending the itch signal to the brain.1 By targeting the IL-31 pathway, Canine Atopic Dermatitis Immunotherapeutic* interrupts the cycle of itch in dogs with atopic dermatitis.

How long does Canine Atopic Dermatitis Immunotherapeutic* remain in the body?

Canine Atopic Dermatitis Immunotherapeutic* remains in circulation for several weeks.2 Like other naturally occurring antibodies and antibody-antigen complexes, it is eliminated via normal protein degradation pathways.

MOA Bottom Banner

A historical perspective on the therapeutic use of antibodies

antibody-science-therapeutic-antibodies-historical-perspective
Itch cycle website

*This product license is conditional. Efficacy and potency test studies in progress.

References: 1. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24:48–53.e11-2. doi:10.1111/j.1365-3164.2012.01098.x. 2. Data on file, Study Report No. C863R-US-12-018. Zoetis LLC.


All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2016 Zoetis Services LLC. All rights reserved. CYT-00078